Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This study comprises of a dose-escalation and dose expansion phase and will determine the
maximum tolerated dose of oral Panobinostat on a continuous schedule in adult in combination
with bortezomib. Safety, tolerability, PK and PD profile of the combined treatments will be
assessed as secondary objectives. Dose expansion phase will explore in a non continuous
Panobinostat schedule with bortezomib and dexamethasone, safety and tolerability and PK
profile of Panobinostat and Bortezomib with and without Dexamethasone